{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T22:58:31Z","timestamp":1773701911953,"version":"3.50.1"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"Supplement_B","license":[{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Despite the sharp decline in most high-income industrialized countries, rheumatic heart disease (RHD) continues to be highly prevalent in many rural, low- and middle-income countries. RHD most frequently involves the mitral valve, both in the form of isolated regurgitation and in the form of regurgitation associated with mitral stenosis (mitral stenosis, MS). Atrial fibrillation (AF) is a common complication of RHD that is independently associated with an increased risk of death, heart failure, and systemic thromboembolism. Few studies have focused on the issue of the best oral anticoagulation strategy for patients with RHD and AF. Randomized trials establishing the non-inferiority of new direct oral anticoagulants (DOACs) over vitamin K antagonists (VKAs) in the prevention of stroke and systemic embolism excluded AF patients with mechanical valves or with moderate-to-severe MS. Nevertheless, variable proportions of patients with other VHD types were included. Recently, the INVICTUS trial demonstrated that in patients with RHD-related AF, direct oral anticoagulant rivaroxaban is inferior to VKAs in preventing stroke, systemic embolism, myocardial infarction, or death and is similar in bleeding risk. These results confirm and reinforce the recommendations of current international guidelines supporting the use of VKAs in patients with RHD-related AF.<\/jats:p>","DOI":"10.1093\/eurheartjsupp\/suad065","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T17:59:48Z","timestamp":1682099988000},"page":"B41-B45","source":"Crossref","is-referenced-by-count":2,"title":["DOACs and rheumatic valvulopathy: always a red light?"],"prefix":"10.1093","volume":"25","author":[{"given":"Carla","family":"Rochira","sequence":"first","affiliation":[{"name":"Cardiology Department, Hospital-University Policlinico \u2018G. Rodolico-San Marco\u2019, University of Catania , Catania , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5156-7723","authenticated-orcid":false,"given":"Davide","family":"Capodanno","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital-University Policlinico \u2018G. Rodolico-San Marco\u2019, University of Catania , Catania , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,4,21]]},"reference":[{"key":"2023042117452586600_suad065-B1","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1056\/NEJMoa1603693","article-title":"Global, regional, and national burden of rheumatic heart disease, 1990\u20132015","volume":"377","author":"Watkins","year":"2017","journal-title":"N Engl J Med"},{"key":"2023042117452586600_suad065-B2","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000000921","article-title":"Contemporary diagnosis and management of rheumatic heart disease: implications for closing the gap: a scientific statement from the American heart association","volume":"142","author":"Kumar","year":"2020","journal-title":"Circulation"},{"key":"2023042117452586600_suad065-B3","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1016\/j.ihj.2018.05.013","article-title":"Prevalence, risk determinants and consequences of atrial fibrillation in rheumatic heart disease: 6 years hospital based-Himachal Pradesh- rheumatic fever\/rheumatic heart disease (HP-RF\/RHD) registry","volume":"70","author":"Negi","year":"2018","journal-title":"Indian Heart J"},{"key":"2023042117452586600_suad065-B4","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the framingham study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"2023042117452586600_suad065-B5","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association for cardio-thoracic surgery (EACTS)","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"2023042117452586600_suad065-B6","article-title":"2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons","volume":"74","author":"January","year":"2019","journal-title":"Circulation"},{"key":"2023042117452586600_suad065-B7","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"2023042117452586600_suad065-B8","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"2023042117452586600_suad065-B9","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"2023042117452586600_suad065-B10","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"2023042117452586600_suad065-B11","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"2023042117452586600_suad065-B12","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1093\/europace\/eux240","article-title":"Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European heart rhythm association (EHRA) and European society of cardiology working group on thrombosis, endorsed by the ESC working group on valvular heart disease","volume":"19","author":"Lip","year":"2017","journal-title":"EP Europace"},{"key":"2023042117452586600_suad065-B13","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.jacc.2016.12.038","article-title":"Non\u2013vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease","volume":"69","author":"Renda","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2023042117452586600_suad065-B14","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"2023042117452586600_suad065-B15","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1161\/CIRCULATIONAHA.115.020950","article-title":"Comparison of dabigatran and warfarin in patients with atrial fibrillation and valvular heart disease","volume":"134","author":"Ezekowitz","year":"2016","journal-title":"Circulation"},{"key":"2023042117452586600_suad065-B16","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1093\/eurheartj\/ehu305","article-title":"Clinical characteristics and outcomes with rivaroxaban vs. Warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial","volume":"35","author":"Breithardt","year":"2014","journal-title":"Eur Heart J"},{"key":"2023042117452586600_suad065-B17","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.114.014807","article-title":"Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease","volume":"132","author":"Avezum","year":"2015","journal-title":"Circulation"},{"key":"2023042117452586600_suad065-B18","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.jacc.2016.12.031","article-title":"Valvular heart disease patients on edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial","volume":"69","author":"de Caterina","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2023042117452586600_suad065-B19","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa2029603","article-title":"Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve","volume":"383","author":"Guimar\u00e3es","year":"2020","journal-title":"N Engl J Med"},{"key":"2023042117452586600_suad065-B20","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1056\/NEJMoa2209051","article-title":"Rivaroxaban in rheumatic heart disease\u2013associated atrial fibrillation","volume":"387","author":"Connolly","year":"2022","journal-title":"N Engl J Med"},{"key":"2023042117452586600_suad065-B21","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1540-8175.2010.01361.x","article-title":"Incidence and predictors of left atrial thrombus in patients with rheumatic mitral stenosis and sinus rhythm: a transesophageal echocardiographic study","volume":"28","author":"Manjunath","year":"2011","journal-title":"Echocardiography"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/25\/Supplement_B\/B41\/50061105\/suad065.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/25\/Supplement_B\/B41\/50061105\/suad065.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T18:00:06Z","timestamp":1682100006000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/25\/Supplement_B\/B41\/7135785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,1]]},"references-count":21,"journal-issue":{"issue":"Supplement_B","published-online":{"date-parts":[[2023,4,21]]},"published-print":{"date-parts":[[2023,4,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartjsupp\/suad065","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"value":"1520-765X","type":"print"},{"value":"1554-2815","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4,1]]},"published":{"date-parts":[[2023,4,1]]}}}